HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME: Take the course for this article: Volume 72, Number 19, May 12, 2009 All Versions of this Article: 01.wnl.0000342388.73185.80v1 72/19/1630    most recent Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Villoslada, P. Articles by Artieda, J. Search for Related Content PubMed PubMed Citation Articles by Villoslada, P. Articles by Artieda, J. Related Collections Clinical trials Randomized controlled (CONSORT agreement) All Cognitive Disorders/Dementia Multiple sclerosis Related Article

Memantine induces reversible neurologic impairment in patients with MS

From the Department of Neurology, University of Navarra, Pamplona, Spain.

Address correspondence and reprint requests to Dr. Pablo Villoslada, Department of Neurology, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain pvilloslada{at}clinic.ub.es

Background: Cognitive dysfunction is very common in multiple sclerosis (MS) and it severely impairs patients’ quality of life. Thus, we explored whether memantine might improve cognitive performance in patients with MS.

Methods: We conducted a pilot trial with memantine (30 mg/day) in patients with MS with cognitive impairment. The trial was designed as a 1-year, randomized, double-blind, crossover study comparing memantine against a placebo in 60 patients with MS and cognitive impairment. Cognitive impairment was defined as the performance 1.5 standard deviations below the normative data in at least two tests of two cognitive domains in the Brief Repeatable Battery–Neuropsychology. The primary endpoint was improvement of verbal memory and the secondary endpoints were safety and improvements in the other cognitive domains, disability and quality of life. The trial was registered at www.clinicaltrials.org: NCT00638833.

Results: Although 19 patients had been included, the trial was halted after nine patients reported a worsening of their neurologic symptoms that deteriorated their quality of life. Seven of the nine patients in the memantine arm had blurred vision, fatigue, severe headache, increased muscle weakness, walking difficulties, or unstable gait. Only two patients in the placebo group reported neurologic symptoms and in both cases they were related with changes in their disease-modifying therapy. The adverse events only occurred on reaching the maximum dose (30 mg/day). After stopping medication, the patients reverted to their baseline disability within a few days.

Conclusions: Memantine at a dose of 30 mg/day may induce transient worsening of neurologic symptoms of multiple sclerosis.

Abbreviations: BRB-N = Brief Repeatable Battery-Neuropsychology; EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; MSFC = MS Functional Composite; PR = progressive relapsing; RR = relapsing remitting; SP = secondary progressive.

Editorial, page 1626

e-Pub ahead of print on December 17, 2008, at www.neurology.org.

Supported by an unrestricted grant from Lundbeck A/S, Denmark. The authors promoted and designed the study, recruited patients, collected, stored and analyzed the data, and wrote the paper independently of the sponsor.

Disclosure: The authors report no disclosures.

Received July 7, 2008. Accepted in final form November 13, 2008.

Related Article

Understanding pseudo: The symptoms are real, the cause is unclear

Ari J. Green
Neurology 2009 72: 1626-1627. [Full Text] [PDF]

This article has been cited by other articles:

				Memantine in MS-Related Cognitive Dysfunction: An Unexpected Outcome Journal Watch Neurology, September 29, 2009; 2009(929): 2 - 2. [Full Text]

				A. J. Green Understanding pseudo: The symptoms are real, the cause is unclear Neurology, May 12, 2009; 72(19): 1626 - 1627. [Full Text] [PDF]